When do science recommendations stop being effective? The case of the sprawl of diesel electricity generators in Beirut.

Lebanon, plagued by political and economic crises, experienced a government collapse in early 2020, leading to an electrical nationwide blackout by 2023. Diesel generators were used to compensate for the absence of power production from the national provider, Electricité du Liban (EDL). To investigate the effect of the crisis on the levels of 16 EPA particle bound polycyclic aromatic hydrocarbons (PPAHs), an annual comparative analysis of three locations within Beirut started in 2022 and ended in 2023.

Association between cannabis use and clinical outcomes in patients with solid malignancies receiving immune checkpoint inhibitors.

Background: Cannabis (CAN) use has risen significantly over the last few decades. CAN has potent immunosuppressive properties, which could antagonize the effect of immunotherapy (IO). The impact of CAN use on clinical cancer outcomes remains unclear.

RCC1 regulation of subcellular protein localization via Ran GTPase drives pancreatic ductal adenocarcinoma growth.

Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy, with limited therapeutic options. Here, we evaluated the role of regulator of chromosome condensation 1 (RCC1) in PDAC. RCC1 functions as a guanine exchange factor for GTP-binding nuclear protein Ran (Ran) GTPase and is involved in nucleocytoplasmic transport.

Health Disparities among Patients with Cancer Who Received Molecular Testing for Biomarker-Directed Therapy.

Health disparities present a barrier to successful oncology treatment. The potential for precision oncology to reduce health disparities has not previously been analyzed. We performed a retrospective analysis of 12,627 patients from six major cancer centers whose tumors underwent molecular testing at Caris Life Sciences between 2010 and 2020.

The phase I/II eNRGy trial: Zenocutuzumab in patients with cancers harboring gene fusions.

Neuregulin 1 () fusions are oncogenic drivers that have been detected in non-small-cell lung cancer (NSCLC), pancreatic ductal adenocarcinoma (PDAC) and other solid tumors. fusions are rare, occurring in less than 1% of solid tumors. Patients with fusion positive (NRG1+) cancer have limited therapeutic options.